Literature DB >> 29914962

In Vitro Activity of Ceftolozane-Tazobactam against Enterobacter cloacae Complex Clinical Isolates with Different β-Lactam Resistance Phenotypes.

Frédéric Robin1,2, Michel Auzou3, Richard Bonnet1,2, Romain Lebreuilly4, Christophe Isnard3,5, Vincent Cattoir6,7, François Guérin2,5.   

Abstract

The study evaluated the in vitro activity of ceftolozane-tazobactam (C/T) against 94 unique clinical isolates of Enterobacter cloacae complex (ECC). No difference was observed according to the ECC cluster. The in vitro activity greatly varied depending on the β-lactamase-producing profile: 100%, 67%, and 19% of wild-type, extended-spectrum β-lactamase (ESBL)-producing, and AmpC-overproducing strains, respectively, were susceptible to C/T. The use of C/T could be of interest for the treatment of some infections caused by ESBL-producing AmpC-nonoverexpressing ECC isolates.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  AmpC; E. cloacae complex; ECC; ESBL; TOL-TAZ; ceftolozane; tazobactam

Mesh：

Substances：

Year:  2018        PMID： 29914962      PMCID： PMC6125531          DOI： 10.1128/AAC.00675-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  19 in total

1.  Detection of plasmid-mediated AmpC beta-lactamase genes in clinical isolates by using multiplex PCR.

Authors:  F Javier Pérez-Pérez; Nancy D Hanson
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

2.  Prevalence of derepressed ampC mutants and extended-spectrum beta-lactamase producers among clinical isolates of Citrobacter freundii, Enterobacter spp., and Serratia marcescens in Korea: dissemination of CTX-M-3, TEM-52, and SHV-12.

Authors:  Jungmin Kim; Yu-Mi Lim
Journal:  J Clin Microbiol       Date:  2005-05       Impact factor: 5.948

3.  Complex Regulation Pathways of AmpC-Mediated β-Lactam Resistance in Enterobacter cloacae Complex.

Authors:  François Guérin; Christophe Isnard; Vincent Cattoir; Jean Christophe Giard
Journal:  Antimicrob Agents Chemother       Date:  2015-10-05       Impact factor: 5.191

Review 4.  Enterobacter cloacae complex: clinical impact and emerging antibiotic resistance.

Authors:  Maria Lina Mezzatesta; Floriana Gona; Stefania Stefani
Journal:  Future Microbiol       Date:  2012-07       Impact factor: 3.165

5.  Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2013-2016) as Part of the Surveillance Program: Program to Assess Ceftolozane-Tazobactam Susceptibility.

Authors:  Dee Shortridge; Michael A Pfaller; Mariana Castanheira; Robert K Flamm
Journal:  Microb Drug Resist       Date:  2017-10-17       Impact factor: 3.431

6.  International study of the prevalence and outcomes of infection in intensive care units.

Authors:  Jean-Louis Vincent; Jordi Rello; John Marshall; Eliezer Silva; Antonio Anzueto; Claude D Martin; Rui Moreno; Jeffrey Lipman; Charles Gomersall; Yasser Sakr; Konrad Reinhart
Journal:  JAMA       Date:  2009-12-02       Impact factor: 56.272

Review 7.  Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations.

Authors:  David van Duin; Robert A Bonomo
Journal:  Clin Infect Dis       Date:  2016-04-20       Impact factor: 9.079

Review 8.  AmpC beta-lactamases.

Authors:  George A Jacoby
Journal:  Clin Microbiol Rev       Date:  2009-01       Impact factor: 26.132

9.  Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).

Authors:  Helio S Sader; David J Farrell; Mariana Castanheira; Robert K Flamm; Ronald N Jones
Journal:  J Antimicrob Chemother       Date:  2014-06-10       Impact factor: 5.790

10.  Population genetics of the nomenspecies Enterobacter cloacae.

Authors:  Harald Hoffmann; Andreas Roggenkamp
Journal:  Appl Environ Microbiol       Date:  2003-09       Impact factor: 4.792
View more
  4 in total

Review 1.  Resistance to Novel β-Lactam-β-Lactamase Inhibitor Combinations: The "Price of Progress".

Authors:  Krisztina M Papp-Wallace; Andrew R Mack; Magdalena A Taracila; Robert A Bonomo
Journal:  Infect Dis Clin North Am       Date:  2020-09-30       Impact factor: 5.982

Review 2.  AmpC β-lactamase-producing Enterobacterales: what a clinician should know.

Authors:  Simone Meini; Carlo Tascini; Marco Cei; Emanuela Sozio; Gian Maria Rossolini
Journal:  Infection       Date:  2019-03-06       Impact factor: 3.553

Review 3.  New Perspectives on Antimicrobial Agents: Ceftolozane-Tazobactam.

Authors:  Bryan D Lizza; Kevin D Betthauser; David J Ritchie; Scott T Micek; Marin H Kollef
Journal:  Antimicrob Agents Chemother       Date:  2021-06-17       Impact factor: 5.191

4.  Activity of ceftolozane-tazobactam and comparators against gram-negative bacilli: Results from the study for monitoring antimicrobial resistance trends (SMART - Brazil; 2016-2017).

Authors:  Elisa Maria Beirão; Suellen da Silva Rodrigues; Tarik Klain de Andrade; Fernando Brandão Serra; Marina Della Negra de Paula; Thales Jose Bueno Polis; Ana Cristina Gales
Journal:  Braz J Infect Dis       Date:  2020-07-12       Impact factor: 3.257
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.